Walleye Capital
KALV

Walleye Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Walleye Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
+79,666
New +$1.28M 0.01% 1649
2025
Q2 		– Sell
-249,161
Closed -$3.05M – 4785
2025
Q1 		$2.88M Sell
249,161
-18,582
-7% -$190K 0.01% 1176
2024
Q4 		$2.27M Buy
+267,743
New +$2.77M 0.01% 1671
2024
Q2 		– Sell
-120,308
Closed -$1.43M – 5793
2024
Q1 		$1.43M Buy
120,308
+22,478
+23% +$300K ﹤0.01% 2249
2023
Q4 		$1.2M Buy
97,830
+39,452
+68% +$359K ﹤0.01% 2210
2023
Q3 		$562K Buy
+58,378
New +$596K ﹤0.01% 2721
2023
Q1 		– Sell
-32,482
Closed -$220K – 4159
2022
Q4 		$220K Sell
32,482
-116,385
-78% -$623K ﹤0.01% 1976
2022
Q3 		$2.16M Sell
148,867
-55,471
-27% -$775K 0.04% 518
2022
Q2 		$2.01M Buy
204,338
+140,128
+218% +$1.55M 0.06% 365
2022
Q1 		$946K Buy
+64,210
New +$923K 0.03% 665
2020
Q3 		– Sell
-16,676
Closed -$202K – 906
2020
Q2 		$202K Sell
16,676
-4,124
-20% -$43.9K 0.05% 433
2020
Q1 		$159K Buy
+20,800
New +$281K 0.04% 492

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's KALV Position: Q1 2026 in Review

Walleye Capital opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 79,666 shares worth $1.6M. The stake represents 0.01% of the portfolio and ranks #1649 among its holdings. This is a return to the name: Walleye Capital previously reported a position in KALV as recently as Q1 2025.

Walleye Capital first reported a position in KALV in Q1 2020 and has held it in 12 quarters since. The position peaked at $2.88M in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Walleye Capital held 79,666 shares of KalVista Pharmaceuticals worth $1.6M as of Q1 2026.
  • KalVista Pharmaceuticals was a new Walleye Capital position in Q1 2026.
  • KalVista Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1649 holding.
  • Walleye Capital first reported a position in KalVista Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
  • Walleye Capital's KalVista Pharmaceuticals position peaked at $2.88M in Q1 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.